Adi Gilboa-Geffen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Adi Gilboa-Geffen has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Hermona Soreq
The Edmond & Lily Safra Center for Brain Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel
9 shared publications Lee Adam Wheeler
Harvard Medical School, Boston, MA
3 shared publications- Anders Wittrup
Department of Clinical Sciences, Oncology, Faculty of Medicine, Lund University, Lund, Sweden
2 shared publications - David Samuel Greenberg
The Edmond and Lily Safra Center for Brain Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel
2 shared publications Fabio Petrocca
Harvard Medical School, Boston, MA
2 shared publications- Geula Hanin
Department of Genetics, University of Cambridge , Cambridge CB23EH
2 shared publications
Latest Publications
- 1 August 2015
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (15_Supplem) , LB-299-299
Abstract LB-299: Gene knockdown by EpCAM aptamer-siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells
Effective therapeutic strategies for in vivo siRNA delivery to knockdown genes in cells outside the liver are needed to harness RNA interference for treating cancer. EpCAM is a tumor-associated antigen highly expressed on common epithelial cancers and their tumor-initiating cells (T-IC, also known as cancer stem cells). Here we show that aptamer-siRNA chimeras (AsiC, an EpCAM aptamer linked to an siRNA sense strand and annealed to the siRNA antisense strand) are selectively taken up and knockdown gene expression in EpCAM+ cancer cells in vitro and in human cancer biopsy tissues. PLK1 EpCAM-AsiCs inhibit colony and mammosphere formation (in vitro T-IC assays) and tumor initiation by EpCAM+ luminal and basal-A triple negative breast cancer (TNBC) cell lines, but not EpCAM- mesenchymal basal-B TNBCs, in nude mice. Subcutaneously administered EpCAM-AsiCs concentrate in EpCAM+ Her2+ and TNBC tumors and suppress their growth. Thus EpCAM-AsiCs provide an attractive approach for treating epithelial cancer. Note: This abstract was not presented at the meeting. Citation Format: Adi Gilboa-Geffen, Peter Hamar, Lee Adam Wheeler, Radiana Trifonova, Fabio Petrocca, Anders Wittrup, Judy Lieberman. Gene knockdown by EpCAM aptamer-siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-299. doi:10.1158/1538-7445.AM2015-LB-299
- 1 August 2015
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (15_Supplem) , LB-299-299
Abstract LB-299: Gene knockdown by EpCAM aptamer-siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells
Effective therapeutic strategies for in vivo siRNA delivery to knockdown genes in cells outside the liver are needed to harness RNA interference for treating cancer. EpCAM is a tumor-associated antigen highly expressed on common epithelial cancers and their tumor-initiating cells (T-IC, also known as cancer stem cells). Here we show that aptamer-siRNA chimeras (AsiC, an EpCAM aptamer linked to an siRNA sense strand and annealed to the siRNA antisense strand) are selectively taken up and knockdown gene expression in EpCAM+ cancer cells in vitro and in human cancer biopsy tissues. PLK1 EpCAM-AsiCs inhibit colony and mammosphere formation (in vitro T-IC assays) and tumor initiation by EpCAM+ luminal and basal-A triple negative breast cancer (TNBC) cell lines, but not EpCAM- mesenchymal basal-B TNBCs, in nude mice. Subcutaneously administered EpCAM-AsiCs concentrate in EpCAM+ Her2+ and TNBC tumors and suppress their growth. Thus EpCAM-AsiCs provide an attractive approach for treating epithelial cancer. Note: This abstract was not presented at the meeting. Citation Format: Adi Gilboa-Geffen, Peter Hamar, Lee Adam Wheeler, Radiana Trifonova, Fabio Petrocca, Anders Wittrup, Judy Lieberman. Gene knockdown by EpCAM aptamer-siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-299. doi:10.1158/1538-7445.AM2015-LB-299
- 1 November 2013
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 12 (11_Supplem) , CN01-02
Abstract CN01-02: Targeting basal-like TNBCs and epithelial tumor-initiating cells with aptamer-siRNA chimeras.
RNA interference (RNAi) offers the exciting therapeutic possibility of selectively knocking down disease-causing genes. Recent Phase I and II clinical trials of small interfering RNAs (siRNAs) have shown promising gene knockdown and clinical benefit in a handful of diverse diseases caused by aberrant liver gene expression. In these studies siRNAs were targeted to the liver by encapsulation in lipoplexes or by conjugation with a sugar selectively recognized by hepatocytes. The major obstacle to harnessing RNAi for treating cancer is the difficulty delivering RNAs into disseminated cancer cells. Giangrande, McNamara and Gilboa developed a flexible and effective multifunctional RNA delivery platform using aptamer-siRNA chimeras (AsiC), to accomplish this goal. RNA aptamers, structured RNAs that bind with high affinity to a protein, covalently linked to siRNAs, cause knockdown selectively in cells bearing the receptor recognized by the aptamer. Although treatment for breast cancer has improved with the development of targeted therapeutics, there is still a need for new approaches for poor prognosis breast cancers. In particular, there is no targeted therapy for triple negative breast cancers (TNBC), which often relapse after current therapy; Her2+ breast cancers frequently develop resistance to targeted therapy with trastuzumab or lapatinib. We chose EpCAM as the receptor for aptamer-targeted treatment of basal-like TNBC because EpCAM is highly expressed on the most malignant epithelial cancers and their tumor-initiating cells (T-ICs). In normal epithelia, EpCAM is only expressed on basolateral gap junctions, where it may not be accessible to drugs. In epithelial cancers, it is not only much more abundant (by several orders of magnitude), but is also distributed along the whole cell membrane. All basal-A TNBC and luminal breast cancer cell lines examined were strongly EpCAM+, while a normal breast cancer epithelial line and mesenchymal TNBCs had close to background EpCAM levels. RNA uptake, gene knockdown and the cytotoxic effect of EpCAM-AsiCs that knockdown PLK1 were robust in basal-like TNBC and luminal breast cancer lines, but not in normal epithelial cells and mesenchymal cells. In fact gene knockdown and antitumor effect correlated with EpCAM expression. EpCAM-AsiCs targeting PLK1, but not control siRNAs, eliminated T-ICs from epithelial TNBC and luminal breast cancer cell lines as assessed by in vitro assays for T-IC function-mammosphere and colony formation and survival of Aldefluor+ cells. These results suggest that EpCAM-AsiCs could be used to treat epithelial breast tumors and the T-ICs within them, sparing normal cells. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):CN01-02. Citation Format: Adi Gilboa-Geffen, Lee Adam Wheeler, Anders Wittrup, Fabio Petrocca, Judy Lieberman. Targeting basal-like TNBCs and epithelial tumor-initiating cells with aptamer-siRNA chimeras. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr CN01-02.
- 1 November 2013
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 12 (11_Supplem) , CN01-02
Abstract CN01-02: Targeting basal-like TNBCs and epithelial tumor-initiating cells with aptamer-siRNA chimeras.
RNA interference (RNAi) offers the exciting therapeutic possibility of selectively knocking down disease-causing genes. Recent Phase I and II clinical trials of small interfering RNAs (siRNAs) have shown promising gene knockdown and clinical benefit in a handful of diverse diseases caused by aberrant liver gene expression. In these studies siRNAs were targeted to the liver by encapsulation in lipoplexes or by conjugation with a sugar selectively recognized by hepatocytes. The major obstacle to harnessing RNAi for treating cancer is the difficulty delivering RNAs into disseminated cancer cells. Giangrande, McNamara and Gilboa developed a flexible and effective multifunctional RNA delivery platform using aptamer-siRNA chimeras (AsiC), to accomplish this goal. RNA aptamers, structured RNAs that bind with high affinity to a protein, covalently linked to siRNAs, cause knockdown selectively in cells bearing the receptor recognized by the aptamer. Although treatment for breast cancer has improved with the development of targeted therapeutics, there is still a need for new approaches for poor prognosis breast cancers. In particular, there is no targeted therapy for triple negative breast cancers (TNBC), which often relapse after current therapy; Her2+ breast cancers frequently develop resistance to targeted therapy with trastuzumab or lapatinib. We chose EpCAM as the receptor for aptamer-targeted treatment of basal-like TNBC because EpCAM is highly expressed on the most malignant epithelial cancers and their tumor-initiating cells (T-ICs). In normal epithelia, EpCAM is only expressed on basolateral gap junctions, where it may not be accessible to drugs. In epithelial cancers, it is not only much more abundant (by several orders of magnitude), but is also distributed along the whole cell membrane. All basal-A TNBC and luminal breast cancer cell lines examined were strongly EpCAM+, while a normal breast cancer epithelial line and mesenchymal TNBCs had close to background EpCAM levels. RNA uptake, gene knockdown and the cytotoxic effect of EpCAM-AsiCs that knockdown PLK1 were robust in basal-like TNBC and luminal breast cancer lines, but not in normal epithelial cells and mesenchymal cells. In fact gene knockdown and antitumor effect correlated with EpCAM expression. EpCAM-AsiCs targeting PLK1, but not control siRNAs, eliminated T-ICs from epithelial TNBC and luminal breast cancer cell lines as assessed by in vitro assays for T-IC function-mammosphere and colony formation and survival of Aldefluor+ cells. These results suggest that EpCAM-AsiCs could be used to treat epithelial breast tumors and the T-ICs within them, sparing normal cells. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):CN01-02. Citation Format: Adi Gilboa-Geffen, Lee Adam Wheeler, Anders Wittrup, Fabio Petrocca, Judy Lieberman. Targeting basal-like TNBCs and epithelial tumor-initiating cells with aptamer-siRNA chimeras. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr CN01-02.
- Open Access
- 1 July 2013
- Published by Elsevier in Molecular Therapy
- Vol. 21 (7) , 1378-1389
Durable Knockdown and Protection From HIV Transmission in Humanized Mice Treated With Gel-formulated CD4 Aptamer-siRNA Chimeras
- 1 July 2013
- Published by Elsevier in Molecular Therapy
- Vol. 21 (7) , 1378-1389
Open AccessDurable Knockdown and Protection From HIV Transmission in Humanized Mice Treated With Gel-formulated CD4 Aptamer-siRNA Chimeras
- Open Access
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 5, 20355
Stressing hematopoiesis and immunity: an acetylcholinesterase window into nervous and immune system interactions
Hematopoietic stem cells (HSC) differentiate and generate all blood cell lineages while maintaining self renewal ability throughout life. Systemic responses to stressful insults, either psychological or physical exert both stimulating and down-regulating effects on these dynamic members of the immune system. Stress-facilitated division and re-oriented differentiation of progenitor cells modifies hematopoietic cell type composition, while enhancing cytokine production and promoting inflammation. Inversely, stress-induced increases in the neurotransmitter acetylcholine act to mitigate inflammatory response and regain homeostasis. This signaling process is terminated when acetylcholine is hydrolyzed by acetylcholinesterase. Alternative splicing, which is stress-modified, changes the composition of acetylcholinesterase variants, modifying their terminal sequences, susceptibility for microRNA suppression and sub-cellular localizations. Intriguingly, the effects of stress and acetylcholinesterase variants on hematopoietic development and inflammation in health and disease are both subject to small molecule as well as oligonucleotide-mediated manipulations in vitro and in vivo. The therapeutic agents can thus be targeted to the enzyme protein, its encoding mRNA transcripts or the regulator microRNA-132, opening new venues for therapeutic interference with multiple nervous and immune system diseases.
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 5, 20355
Open AccessStressing hematopoiesis and immunity: an acetylcholinesterase window into nervous and immune system interactions
Hematopoietic stem cells (HSC) differentiate and generate all blood cell lineages while maintaining self renewal ability throughout life. Systemic responses to stressful insults, either psychological or physical exert both stimulating and down-regulating effects on these dynamic members of the immune system. Stress-facilitated division and re-oriented differentiation of progenitor cells modifies hematopoietic cell type composition, while enhancing cytokine production and promoting inflammation. Inversely, stress-induced increases in the neurotransmitter acetylcholine act to mitigate inflammatory response and regain homeostasis. This signaling process is terminated when acetylcholine is hydrolyzed by acetylcholinesterase. Alternative splicing, which is stress-modified, changes the composition of acetylcholinesterase variants, modifying their terminal sequences, susceptibility for microRNA suppression and sub-cellular localizations. Intriguingly, the effects of stress and acetylcholinesterase variants on hematopoietic development and inflammation in health and disease are both subject to small molecule as well as oligonucleotide-mediated manipulations in vitro and in vivo. The therapeutic agents can thus be targeted to the enzyme protein, its encoding mRNA transcripts or the regulator microRNA-132, opening new venues for therapeutic interference with multiple nervous and immune system diseases.
- Open Access
- 9 December 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (12) , e28727
Activation of the Alternative NFκB Pathway Improves Disease Symptoms in a Model of Sjogren's Syndrome
The purpose of our study was to understand if Toll-like receptor 9 (TLR9) activation could contribute to the control of inflammation in Sjogren's syndrome. To this end, we manipulated TLR9 signaling in non-obese diabetic (NOD) and TLR9−/− mice using agonistic CpG oligonucleotide aptamers, TLR9 inhibitors, and the in-house oligonucleotide BL-7040. We then measured salivation, inflammatory response markers, and expression of proteins downstream to NF-κB activation pathways. Finally, we labeled proteins of interest in salivary gland biopsies from Sjogren's syndrome patients, compared to Sicca syndrome controls. We show that in NOD mice BL-7040 activates TLR9 to induce an alternative NF-κB activation mode resulting in increased salivation, elevated anti-inflammatory response in salivary glands, and reduced peripheral AChE activity. These effects were more prominent and also suppressible by TLR9 inhibitors in NOD mice, but TLR9−/− mice were resistant to the salivation-promoting effects of CpG oligonucleotides and BL-7040. Last, salivary glands from Sjogren's disease patients showed increased inflammatory and decreased anti-inflammatory biomarkers, in addition to decreased levels of alternative NF-κB pathway proteins. In summary, we have demonstrated that activation of TLR9 by BL-7040 leads to non-canonical activation of NF-κB, promoting salivary functioning and down-regulating inflammation. We propose that BL-7040 could be beneficial in treating Sjogren's syndrome and may be applicable to additional autoimmune syndromes.
- 9 December 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (12) , e28727
Open AccessActivation of the Alternative NFκB Pathway Improves Disease Symptoms in a Model of Sjogren's Syndrome
The purpose of our study was to understand if Toll-like receptor 9 (TLR9) activation could contribute to the control of inflammation in Sjogren's syndrome. To this end, we manipulated TLR9 signaling in non-obese diabetic (NOD) and TLR9−/− mice using agonistic CpG oligonucleotide aptamers, TLR9 inhibitors, and the in-house oligonucleotide BL-7040. We then measured salivation, inflammatory response markers, and expression of proteins downstream to NF-κB activation pathways. Finally, we labeled proteins of interest in salivary gland biopsies from Sjogren's syndrome patients, compared to Sicca syndrome controls. We show that in NOD mice BL-7040 activates TLR9 to induce an alternative NF-κB activation mode resulting in increased salivation, elevated anti-inflammatory response in salivary glands, and reduced peripheral AChE activity. These effects were more prominent and also suppressible by TLR9 inhibitors in NOD mice, but TLR9−/− mice were resistant to the salivation-promoting effects of CpG oligonucleotides and BL-7040. Last, salivary glands from Sjogren's disease patients showed increased inflammatory and decreased anti-inflammatory biomarkers, in addition to decreased levels of alternative NF-κB pathway proteins. In summary, we have demonstrated that activation of TLR9 by BL-7040 leads to non-canonical activation of NF-κB, promoting salivary functioning and down-regulating inflammation. We propose that BL-7040 could be beneficial in treating Sjogren's syndrome and may be applicable to additional autoimmune syndromes.
- 1 August 2011
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-3
Prophylactic oligonucleotide-mediated enhancement of host acetylcholinesterase protects from organophosphate poisoning
Acute organophosphate (OP) poisoning is lethal due to irreversible acetylcholinesterase (AChE) inhibition in neuromuscular junctions (NMJ). Recently, we discovered that AChE levels are down-regulated by microRNA-132 (miR-132) and that blocking this down-regulation can significantly elevate endogenous AChE levels [1]. Here, we report effective prophylactic protection from paraoxon poisoning of BalbC mice injected intravenously (IV) 24 hours pre-exposure with 3.3 mg/kg AM132, a 22-mer antisense chemically protected from nuclease degradation by 2'-0-methyl modified bases on a phosphorothioate backbone and conjugated to cholesterol at its 3 end for enhanced penetration. When exposed to 0.9LD50 paraoxon, all naive but none of the Chol-AM132-protected mice exhibited severe poisoning symptoms (Mann-Whitney U-test, P=0.028, N=4/group). 1.3LD50 exposure caused poisoning symptoms in all mice, but 40% of the Chol-AM132-treated mice survived and recovered, while naive ones all showed severe poisoning symptoms and died within 3 minutes post-exposure (ANOVA P=6.62E-12, N=4-7/group). No mice survived exposure to 10LD50 Paraoxon, but Chol-AM132 treatment conspicuously extended survival time compared to controls (ANOVA P=6.8E-9, N=5/group). To identify the underlying mechanism, we measured AChE activity in NMJs of diaphragm muscle from mice that had been injected with either Chol-AM132 or PBS for 3 successive days. Chol-AM132 treated mice had 10.9±4.2 compared to 6.3±2.7 stained NMJs/ field in control mice (t test, P=0.0069, N=5 mice/group and 18 fields/specimen), possibly reflecting increased expression of AChE in pre-existing NMJs, development of new ones or both. Additionally, Chol-AM132 treatment elevated AChE activity in bone marrow macrophages (29.0±15.0 vs. 14.1±2.6 compared to 15.0±6.4 vs. 9.8±1.2 nmol substrate hydrolyzed/mg protein/min for 3 and 1 day treatment, respectively; Student's t-test: <;0.0065), further predicting potential protection from post-exposure inflammatory insults. Importantly, Chol-AM132 can be synthesized in unlimited amounts using standard equipment, exhibits long-term stability at room temperature and field conditions, and unlike pyridostigmine, does not inhibit pre-existing AChE. Our findings open new venues for prophylactic protection against nerve gas poisoning.
- 1 August 2011
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-3
Prophylactic oligonucleotide-mediated enhancement of host acetylcholinesterase protects from organophosphate poisoning
Acute organophosphate (OP) poisoning is lethal due to irreversible acetylcholinesterase (AChE) inhibition in neuromuscular junctions (NMJ). Recently, we discovered that AChE levels are down-regulated by microRNA-132 (miR-132) and that blocking this down-regulation can significantly elevate endogenous AChE levels [1]. Here, we report effective prophylactic protection from paraoxon poisoning of BalbC mice injected intravenously (IV) 24 hours pre-exposure with 3.3 mg/kg AM132, a 22-mer antisense chemically protected from nuclease degradation by 2'-0-methyl modified bases on a phosphorothioate backbone and conjugated to cholesterol at its 3 end for enhanced penetration. When exposed to 0.9LD50 paraoxon, all naive but none of the Chol-AM132-protected mice exhibited severe poisoning symptoms (Mann-Whitney U-test, P=0.028, N=4/group). 1.3LD50 exposure caused poisoning symptoms in all mice, but 40% of the Chol-AM132-treated mice survived and recovered, while naive ones all showed severe poisoning symptoms and died within 3 minutes post-exposure (ANOVA P=6.62E-12, N=4-7/group). No mice survived exposure to 10LD50 Paraoxon, but Chol-AM132 treatment conspicuously extended survival time compared to controls (ANOVA P=6.8E-9, N=5/group). To identify the underlying mechanism, we measured AChE activity in NMJs of diaphragm muscle from mice that had been injected with either Chol-AM132 or PBS for 3 successive days. Chol-AM132 treated mice had 10.9±4.2 compared to 6.3±2.7 stained NMJs/ field in control mice (t test, P=0.0069, N=5 mice/group and 18 fields/specimen), possibly reflecting increased expression of AChE in pre-existing NMJs, development of new ones or both. Additionally, Chol-AM132 treatment elevated AChE activity in bone marrow macrophages (29.0±15.0 vs. 14.1±2.6 compared to 15.0±6.4 vs. 9.8±1.2 nmol substrate hydrolyzed/mg protein/min for 3 and 1 day treatment, respectively; Student's t-test: <;0.0065), further predicting potential protection from post-exposure inflammatory insults. Importantly, Chol-AM132 can be synthesized in unlimited amounts using standard equipment, exhibits long-term stability at room temperature and field conditions, and unlike pyridostigmine, does not inhibit pre-existing AChE. Our findings open new venues for prophylactic protection against nerve gas poisoning.
- Open Access
- 11 June 2008
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (6) , e2392
Identifying Alternative Hyper-Splicing Signatures in MG-Thymoma by Exon Arrays
The vast majority of human genes (>70%) are alternatively spliced. Although alternative pre-mRNA processing is modified in multiple tumors, alternative hyper-splicing signatures specific to particular tumor types are still lacking. Here, we report the use of Affymetrix Human Exon Arrays to spot hyper-splicing events characteristic of myasthenia gravis (MG)-thymoma, thymic tumors which develop in patients with MG and discriminate them from colon cancer changes. We combined GO term to parent threshold-based and threshold-independent ad-hoc functional statistics with in-depth analysis of key modified transcripts to highlight various exon-specific changes. These denote alternative splicing in MG-thymoma tumors compared to healthy human thymus and to in-house and Affymetrix datasets from colon cancer and healthy tissues. By using both global and specific, term-to-parent Gene Ontology (GO) statistical comparisons, our functional integrative ad-hoc method allowed the detection of disease-relevant splicing events. Hyper-spliced transcripts spanned several categories, including the tumorogenic ERBB4 tyrosine kinase receptor and the connective tissue growth factor CTGF, as well as the immune function-related histocompatability gene HLA-DRB1 and interleukin (IL)19, two muscle-specific collagens and one myosin heavy chain gene; intriguingly, a putative new exon was discovered in the MG-involved acetylcholinesterase ACHE gene. Corresponding changes in spliceosome composition were indicated by co-decreases in the splicing factors ASF/SF2 and SC35. Parallel tumor-associated changes occurred in colon cancer as well, but the majority of the apparent hyper-splicing events were particular to MG-thymoma and could be validated by Fluorescent In-Situ Hybridization (FISH), Reverse Transcription–Polymerase Chain Reaction (RT-PCR) and mass spectrometry (MS) followed by peptide sequencing. Our findings demonstrate a particular alternative hyper-splicing signature for transcripts over-expressed in MG-thymoma, supporting the hypothesis that alternative hyper-splicing contributes to shaping the biological functions of these and other specialized tumors and opening new venues for the development of diagnosis and treatment approaches.
- 11 June 2008
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (6) , e2392
Open AccessIdentifying Alternative Hyper-Splicing Signatures in MG-Thymoma by Exon Arrays
The vast majority of human genes (>70%) are alternatively spliced. Although alternative pre-mRNA processing is modified in multiple tumors, alternative hyper-splicing signatures specific to particular tumor types are still lacking. Here, we report the use of Affymetrix Human Exon Arrays to spot hyper-splicing events characteristic of myasthenia gravis (MG)-thymoma, thymic tumors which develop in patients with MG and discriminate them from colon cancer changes. We combined GO term to parent threshold-based and threshold-independent ad-hoc functional statistics with in-depth analysis of key modified transcripts to highlight various exon-specific changes. These denote alternative splicing in MG-thymoma tumors compared to healthy human thymus and to in-house and Affymetrix datasets from colon cancer and healthy tissues. By using both global and specific, term-to-parent Gene Ontology (GO) statistical comparisons, our functional integrative ad-hoc method allowed the detection of disease-relevant splicing events. Hyper-spliced transcripts spanned several categories, including the tumorogenic ERBB4 tyrosine kinase receptor and the connective tissue growth factor CTGF, as well as the immune function-related histocompatability gene HLA-DRB1 and interleukin (IL)19, two muscle-specific collagens and one myosin heavy chain gene; intriguingly, a putative new exon was discovered in the MG-involved acetylcholinesterase ACHE gene. Corresponding changes in spliceosome composition were indicated by co-decreases in the splicing factors ASF/SF2 and SC35. Parallel tumor-associated changes occurred in colon cancer as well, but the majority of the apparent hyper-splicing events were particular to MG-thymoma and could be validated by Fluorescent In-Situ Hybridization (FISH), Reverse Transcription–Polymerase Chain Reaction (RT-PCR) and mass spectrometry (MS) followed by peptide sequencing. Our findings demonstrate a particular alternative hyper-splicing signature for transcripts over-expressed in MG-thymoma, supporting the hypothesis that alternative hyper-splicing contributes to shaping the biological functions of these and other specialized tumors and opening new venues for the development of diagnosis and treatment approaches.
- 3 May 2007
- Published by Springer Nature in Leukemia
- Vol. 21 (7) , 1472-1480
Acetylcholinesterase/C terminal binding protein interactions modify Ikaros functions, causing T lymphopenia
Hematological changes induced by various stress stimuli are accompanied by replacement of the primary acetylcholinesterase (AChE) 3' splice variant acetylcholinesterase-S (AChE-S) with the myelopoietic acetylcholinesterase-R (AChE-R) variant. To search for putative acetylcholinesterase-S interactions with hematopoietic pathways, we employed a yeast two-hybrid screen. The transcriptional co-repressor C-terminal binding protein (CtBP) was identified as a protein partner of the AChE-S C terminus. In erythroleukemic K562 cells, AChE-S displayed nuclear colocalization and physical interaction with CtBP. Furthermore, co-transfected AChE-S reduced the co-repressive effect of CtBP over the hematopoietic transcription factor, Ikaros. In transgenic mice, overexpressed human (h) AChE-S mRNA induced selective bone marrow upregulation of Ikaros while suppressing FOG, another transcriptional partner of CtBP. Transgenic bone marrow cells showed a correspondingly elevated potential for producing progenitor colonies, compared with controls, while peripheral blood showed increased erythrocyte counts as opposed to reduced platelets, granulocytes and T lymphocytes. AChE's 3' alternative splicing, and the corresponding changes in AChE-S/CtBP interactions, thus emerge as being actively involved in controlling hematopoiesis and the potential for modulating immune functions, supporting reports on malfunctioning immune reactions under impaired splice site selection.
- 3 May 2007
- Published by Springer Nature in Leukemia
- Vol. 21 (7) , 1472-1480
Acetylcholinesterase/C terminal binding protein interactions modify Ikaros functions, causing T lymphopenia
Hematological changes induced by various stress stimuli are accompanied by replacement of the primary acetylcholinesterase (AChE) 3' splice variant acetylcholinesterase-S (AChE-S) with the myelopoietic acetylcholinesterase-R (AChE-R) variant. To search for putative acetylcholinesterase-S interactions with hematopoietic pathways, we employed a yeast two-hybrid screen. The transcriptional co-repressor C-terminal binding protein (CtBP) was identified as a protein partner of the AChE-S C terminus. In erythroleukemic K562 cells, AChE-S displayed nuclear colocalization and physical interaction with CtBP. Furthermore, co-transfected AChE-S reduced the co-repressive effect of CtBP over the hematopoietic transcription factor, Ikaros. In transgenic mice, overexpressed human (h) AChE-S mRNA induced selective bone marrow upregulation of Ikaros while suppressing FOG, another transcriptional partner of CtBP. Transgenic bone marrow cells showed a correspondingly elevated potential for producing progenitor colonies, compared with controls, while peripheral blood showed increased erythrocyte counts as opposed to reduced platelets, granulocytes and T lymphocytes. AChE's 3' alternative splicing, and the corresponding changes in AChE-S/CtBP interactions, thus emerge as being actively involved in controlling hematopoiesis and the potential for modulating immune functions, supporting reports on malfunctioning immune reactions under impaired splice site selection.
- 1 February 2007
- Published by American Society of Hematology in Blood
- Vol. 109 (10) , 4383-4391
The thymic theme of acetylcholinesterase splice variants in myasthenia gravis
Cholinergic signaling and acetylcholinesterase (AChE) influence immune response and inflammation. Autoimmune myasthenia gravis (MG) is mediated by antibodies to the acetylcholine receptor and current therapy is based on anti-AChE drugs. MG is associated with thymic hyperplasia, showing signs of inflammation. The objectives of this study were to analyze the involvement of AChE variants in thymic hyperplasia. We found lower hydrolytic activities in the MG thymus compared with adult controls, accompanied by translocation of AChE-R from the cytoplasm to the membrane and increased expression of the signaling protein kinase PKC-βII. To explore possible causal association of AChE-R changes with thymic composition and function, we used an AChE-R transgenic model and showed smaller thymic medulla compared with strain-matched controls, indicating that AChE-R overexpression interferes with thymic differentiation mechanisms. Interestingly, AChE-R transgenic mice showed increased numbers of CD4+CD8+ cells that were considerably more resistant in vitro to apoptosis than normal thymocytes, suggesting possibly altered positive selection. We further analyzed microarray data of MG thymic hyperplasia compared with healthy controls and found continuous and discrete changes in AChE-annotated GO categories. Together, these findings show that modified AChE gene expression and properties are causally involved in thymic function and development.
- 1 February 2007
- Published by American Society of Hematology in Blood
- Vol. 109 (10) , 4383-4391
The thymic theme of acetylcholinesterase splice variants in myasthenia gravis
Cholinergic signaling and acetylcholinesterase (AChE) influence immune response and inflammation. Autoimmune myasthenia gravis (MG) is mediated by antibodies to the acetylcholine receptor and current therapy is based on anti-AChE drugs. MG is associated with thymic hyperplasia, showing signs of inflammation. The objectives of this study were to analyze the involvement of AChE variants in thymic hyperplasia. We found lower hydrolytic activities in the MG thymus compared with adult controls, accompanied by translocation of AChE-R from the cytoplasm to the membrane and increased expression of the signaling protein kinase PKC-βII. To explore possible causal association of AChE-R changes with thymic composition and function, we used an AChE-R transgenic model and showed smaller thymic medulla compared with strain-matched controls, indicating that AChE-R overexpression interferes with thymic differentiation mechanisms. Interestingly, AChE-R transgenic mice showed increased numbers of CD4+CD8+ cells that were considerably more resistant in vitro to apoptosis than normal thymocytes, suggesting possibly altered positive selection. We further analyzed microarray data of MG thymic hyperplasia compared with healthy controls and found continuous and discrete changes in AChE-annotated GO categories. Together, these findings show that modified AChE gene expression and properties are causally involved in thymic function and development.